Daily CSR
Daily CSR

Daily CSR

Daily news about corporate social responsibility, ethics and sustainability
Tags (7) : biotechnology

Insilico Medicine & ASKA Partner to Advance AI-Driven Treatments for Gynecological Diseases

Insilico Medicine & ASKA Partner to Advance AI-Driven Treatments for Gynecological Diseases
03/25/2026 | Companies
Insilico Medicine, a clinical-stage biotechnology company specializing in generative artificial intelligence (AI) for drug discovery and development, has announced a strategic research partnership with ASKA Pharmaceutical Co., Ltd. (“ASKA”), a pharmaceutical firm focused on internal medicine,...
adenomyosis, AI drug discovery, artificial intelligence in healthcare, ASKA Pharmaceutical, biotechnology, clinical-stage research, disease target identification, drug development, endometriosis, generative AI, gynecological diseases, Insilico Medicine, medical innovation, PandaOmics, pharmaceutical collaboration, reproductive health, TargetPro, therapeutic targets, uterine fibroids, women’s health

Vimgreen Secures IND Approval for VG081821 in NASH Treatment

Vimgreen Secures IND Approval for VG081821 in NASH Treatment
03/18/2026 | Companies
Vimgreen Pharmaceuticals, a prominent company focused on modulating adenosine signaling pathways, has announced that China’s Center for Drug Evaluation (CDE) has cleared its Investigational New Drug (IND) application for VG081821 in non-alcoholic steatohepatitis (NASH), now more commonly termed...
A2A receptor antagonist, adenosine signalling, biotechnology, China CDE, clinical trials, drug development, fibrosis, hepatology, IND approval, inflammation, inverse agonist, lipophagy, liver disease, MASH, metabolic disorders, metabolic dysfunction associated steatohepatitis, NASH, non alcoholic steatohepatitis, Parkinsons disease, Phase II trial, resmetirom, semaglutide, steatosis, VG081821, Vimgreen Pharmaceuticals

HotSpot Therapeutics, Inc. to Present IRF5 Lupus Preclinical Data at European Lupus Meeting 2026

HotSpot Therapeutics, Inc. to Present IRF5 Lupus Preclinical Data at European Lupus Meeting 2026
02/26/2026 | Companies
HotSpot Therapeutics, Inc., a biotech firm focused on advancing oral, allosteric small-molecule therapies that engage natural regulatory pockets, has announced plans to share preclinical findings from its interferon regulatory factor 5 (IRF5) research program at the 15th European Lupus Meeting,...
allosteric therapies, autoimmune disease, biotechnology, drug development, European Lupus Meeting 2026, HotSpot Therapeutics, Inc., interferon regulatory factor 5, IRF5 program, Lisbon Portugal, lupus research, poster presentation, preclinical data, small molecule inhibitors, targeted therapies

Hyundai Bioscience Launches U.S. Phase 2 Trials for Broad-Spectrum Antiviral Xafty

Hyundai Bioscience Launches U.S. Phase 2 Trials for Broad-Spectrum Antiviral Xafty
01/15/2026 | Companies
Hyundai Bioscience has revealed an ambitious new plan aimed at addressing worldwide viral outbreaks, confirming the launch of its Phase 2 clinical trials in the United States. During its presentation at Biotech Showcase 2026, the company outlined a forward-looking antiviral approach centered on...
antiviral drug development, basket trial, Biotech Showcase 2026, biotechnology, broad-spectrum antiviral, clinical research, COVID-19 variants, dengue fever, FDA IND application, global health, Hyundai Bioscience, infectious diseases, influenza, multi-viral treatment, pharmaceutical innovation, Phase 2 clinical trials, public health strategy, RSV, tripledemic, viral epidemics, virus prevention, Xafty

Advancing Cancer Treatment: Cell Therapy Insights from Kite Pharma

Advancing Cancer Treatment: Cell Therapy Insights from Kite Pharma
04/07/2025 | Companies
We're committed to advancing innovation in virology, oncology, and immunology, with a strong emphasis on supporting groundbreaking science that transforms cancer treatment. In the newest episode of The Centrifuge Sessions, Dr. Samuel Haile, Director of Cell Biology at Kite Pharma, shares insights...
biotechnology, cancer innovation, cancer research, cancer treatment, cell biology, cell therapy, immunology, innovative medicine, Kite Pharma, oncology, patient hope, Samuel Haile, The Centrifuge Sessions, virology

Breakthrough HIV Treatment: Gilead's Innovative Drug Discovery Journey

Breakthrough HIV Treatment: Gilead's Innovative Drug Discovery Journey
04/03/2025 | Companies
In 2006, Tomas Cihlar was well aware that, despite initial successes with combination therapy, HIV continued to be a global challenge with limited treatment options. At the time, he had been researching virology at Gilead for 12 years, and the first once-daily, single-tablet regimen for HIV...
antiviral therapy, biopharmaceuticals, biotechnology, breakthrough medicine, clinical trials, drug discovery, drug resistance, Gilead, global health, healthcare innovation, HIV, HIV prevention, HIV research, HIV treatment, medical innovation, medical science, pharmaceutical development, Tomas Cihlar, viral capsid, virology

Brii Biosciences Acquires Full Rights to BRII-179 for HBV Cure Advancement

Brii Biosciences Acquires Full Rights to BRII-179 for HBV Cure Advancement
01/01/2025 | Companies
Brii Biosciences Limited, a biotechnology company focused on developing treatments for diseases with significant unmet needs, announced its acquisition of intellectual property (IP) and other assets related to BRII-179 from VBI Vaccines, Inc., its subsidiaries, and creditors K2 VBI Equity Trust,...
biotechnology, Brii Biosciences, BRII-179, clinical trials, combination therapies, drug development, elebsiran, ENRICH study, functional cure, HBV, healthcare innovation, Hepatitis B Virus, intellectual property acquisition, know-how, patents, PEG-IFNα, Phase 2b study, shareholder value, unmet medical needs, VBI Vaccines


Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com